- HTBX +38% on ahead of planned equity offering.
- KPTI +22% on treatment effect in mid-stage myeloma study.
- NTRI +11% on Q1 result.
- HLIT +11% on Q1 result
- SCYX +9% as FDA has granted both qualified infectious disease product and fast track designations for the treatment of vulvovaginal candidiasis and for the prevention of recurrent VVC.
- UAVS +8%.
- MTZ +6% on Q1 result.
- ABBV +6% on buyback.
- IDTI +6% on Q4 result.
- BLDP +6% on receiving purchase order for 40 Fuel Cell Modules.
- APTI +5% on Q1 result.
Premarket Gainers as of 9:05 am (05/01/2018)
Recommended For You
About SCPX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SCPX | - | - |
Scorpius Holdings, Inc. |